What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 5 months ago
Seminal Articles on Stills disease Tues Nite Rheum Journal Club tommorrow
Discussants: Drs. Bella Mehta, Michael Weisman & Jack Cush
7pm EDT (4pmPDT) - The 1st articles on AOSD from Bywaters & Bujak https://t.co/yRgHlmZHhi
https://t.co/ooexkgM6ga
Register: https://t.co/kstge3gAcl https://t.co/XjQJi4FRmt
Dr. John Cush RheumNow
3 years 5 months ago
Study of 50 #AOSD pts refractory to steroids (n=11), DMARDs (34) & biologics (n 30): given canakinumab 150–300 mg q 4wk (47) or q8wk(3). W/ 27 mos F/U: 78% complete resp w/in 3 mos (20% partial). Steroid sparing in 1/2, Low WBC 6%, 4%SIE https://t.co/QMCLictdrL https://t.co/5hkUOBFDG0
Dr. John Cush RheumNow
3 years 5 months ago
Myths & Misconceptions with Febrile Disorders
Dr. Rachel Tate ( @uptotate) weighs on the myths and misconceptions with Still's disease and autoinflammatory disorders.
https://t.co/z0KHbxnLjJ https://t.co/ymsXYDP5Zs
Dr. John Cush RheumNow
3 years 5 months ago
QD Clinic - Stills (or Not); A Wife's Letter
A letter from the wife of a hospitalized febrile patient says it all.
But, is this Still's disease or not?
https://t.co/MpPbDU9ZTB https://t.co/BqpusOKKLq
Dr. John Cush RheumNow
3 years 5 months ago
213 #SLE pts were screened for Cryoglobulinemia (2013 -2017); CG is frequent in SLE (66%), but mostly asymptomatic. Mean levels 40mg/L (0-228). Cryo Vasculitis in 15% w/ purpura, ulcers, digit ischemia, arthritis, GN (5%) or CNS (19%) https://t.co/R6xUJldgC2 https://t.co/mwsSTI3ztk
Dr. John Cush RheumNow
3 years 5 months ago
Can Antimalarials be Withdrawn in Quiescent Lupus?
Antimalaria (AM) therapy is a cornerstone to the management of systemic lupus erythematosus (SLE), yet a recent study suggests that slowly tapering AM yields a lower rate of SLE flares.
https://t.co/dYJy5BOKay https://t.co/pgz694ep2G
Dr. John Cush RheumNow
3 years 5 months ago
Still’s Disease FAQs
What is the classic 'triad' of Still's disease? Does it affect males and females equally? What are typical lab findings? Which drugs are effective at treating Still's, and which ones are not? What about complications? Read on...
https://t.co/rsFHNPwo9Y https://t.co/AUP1GpbDaN
Many clinicians may not have seen a case of AOSD during training, which overall leads to several delays in referrals and appropriate diagnosis for AOSD patients. AOSD is an autoinflammatory disease where innate immunity plays a primary role and is characterized by seemingly unprovoked inflammation, but without the high-titer autoantibodies or antigen specific T cells seen in autoimmune diseases.
Dr. John Cush RheumNow
3 years 5 months ago
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ
Dr. John Cush RheumNow
3 years 5 months ago
Metanalysis (48 pubs, 145 refract pts) of JAK inhibitors in myositis (DM, JDM) shows significant improvement in skin lesions, muscle weakness, and ILD. https://t.co/cYZ1YEGBOr https://t.co/MDNTSje6a2
Dr. John Cush RheumNow
3 years 5 months ago
10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/2RjGU6Fw2j https://t.co/r7Dsqtksh5
Dr. John Cush RheumNow
3 years 5 months ago
Watch: Comanagement of Psoriasis and Psoriatic Arthritis
https://t.co/oo2Vhiwubq https://t.co/iikYssIepQ
Dr. John Cush RheumNow
3 years 5 months ago
New download available! We're providing an introduction to Still's Disease.
https://t.co/67XzncaUef https://t.co/gaMNGk0grn
Dr. John Cush RheumNow
3 years 5 months ago
MTX + Pegloticase Combo FDA Approved
Horizon has announced that the FDA has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.
https://t.co/D71dmMuB9B https://t.co/jonfLqQ0lj
Poster Hall